Basal Cell Carcinoma Data Steal Show In Verrica’s Q2 Earnings
The company plans an end-of-Phase II meeting with the FDA for VP-315, for which it announced positive Phase II data indicating potential as a frontline treatment.
The company plans an end-of-Phase II meeting with the FDA for VP-315, for which it announced positive Phase II data indicating potential as a frontline treatment.